Intuitive Surgical turned in a second-quarter performance that most companies would envy: revenue of $2.89 billion, a 19% year-on-year gain that handily beat analyst forecasts, and adjusted earnings per share of $2.80 that also topped expectations. Wall Street responded by sending the stock into its steepest single-day decline in months, lopping off more than 14% of its value. The disconnect between stellar reported numbers and a brutal market reception has left investors wrestling with a single question: is the da Vinci franchise merely experiencing a temporary hiccup, or does the deceleration signal something more structural?
The culprit wasn’t the backward-looking data but the forward guidance. Management reaffirmed its full-year 2026 forecast for da Vinci procedure growth of 13.5% to 15.5% — a range many had hoped would be raised after such a strong first half. The decision to hold steady effectively told the market that the pace of procedures in the second half would slow, and investors piled out of the shares accordingly. The stock now trades at roughly €302, barely above a fresh 52-week low of €301.05, and has surrendered about 42% since its January peak of €516.50.
The soft spot is most visible in the United States. Procedure growth there decelerated to 12% in the second quarter from 14% in the first, marking the weakest expansion since the pandemic-era lull of 2020 and 2021. The installed base in the U.S. expanded by only 8.7%. Chief Executive David Rosa attributed the slowdown to changes in patient insurance coverage tied to the Affordable Care Act. Expiring premium subsidies, he explained, have led to coverage lapses that are pushing some patients to delay or forgo procedures. That explanation puts Intuitive at odds with Abbott Laboratories, a competitor that recently dismissed the idea that ACA-related insurance shifts would weigh on med-tech demand.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Globally, procedure growth was a healthier 16%, and the company placed 468 da Vinci systems during the quarter, including 246 of the newest da Vinci 5 generation. Analysts broadly acknowledge that the underlying business is sound — revenue, profit, system placements, and procedure growth all cleared consensus. But the stock’s rich valuation amplified the sting of unchanged guidance. “At a multiple like this, steady isn’t good enough,” noted William Blair, which kept its “Outperform” rating even as it characterized the post-earnings sell-off as a reaction to “overblown expectations.”
The analyst community has responded with an unusually coordinated round of price-target cuts. Leerink slashed its target to $454 from $573, and Citi trimmed to $500 from $590, both maintaining their buy-equivalent ratings. Raymond James went to $483, RBC Capital to $575, and Stifel to $550. Wells Fargo’s Larry Biegelsen cut deeply from $654 to $487 but stuck with an “Overweight” call. BTIG, Baird, JPMorgan, and Mizuho also lowered their targets, with the latter the only house at “Hold” and a $400 mark. Even Bernstein, which still holds the Street’s highest target at $685, reduced it from $750. The consensus rating, however, remains “Moderate Buy,” and the average target of roughly $558 sits well above the current share price.
Beyond the insurance overhang, analysts cite other headwinds: growing competition in China, natural deceleration as the installed base ages, and pricing initiatives that could fuel margin pressure. Still, the technical picture is flashing oversold. The 14-day relative strength index has slipped to around 29.8, a level that historically has preceded stabilization. Whether that turning point materializes depends on whether the U.S. procedure slowdown proves to be a transient insurance effect or the beginning of a more persistent growth fade — a distinction that will likely take another quarter or two to resolve.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from July 20 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 20.
Intuitive Surgical: Buy or sell? Read more here...
